• 我要登录|
  • 免费注册
    |
  • 我的丁香通
    • 企业机构:
    • 成为企业机构
    • 个人用户:
    • 个人中心
  • 移动端
    移动端
丁香通 logo丁香实验_LOGO
搜实验

    大家都在搜

      大家都在搜

        0 人通过求购买到了急需的产品
        免费发布求购
        发布求购
        点赞
        收藏
        wx-share
        分享

        Anti-c-erb-B-2 Ribozyme for Breast Cancer

        互联网

        1147
        Our laboratory has investigated the cleavage activity of an-anti-c-erb -B-2 ribozyme. The c-erb -B-2 proto-oncogene (also called HER-2/neu ) encodes a 185 kDa transmembrane tyrosine kinase-type receptor that is homologous with the epidermal growth factor receptor (EGFR) (1 ,2 ) The putative ligand for c-erb -B-2 is thought to be gp30; however, its role in this process remains to be elucidated (3 ) Although EGFR can transform mouse NIH3T3 cells only in the presence of ligand and receptor (4 ), c-erb -B-2 overexpression can transform NIH3T3 cells in a ligand-independent manner (5 ,6 ). The c-erb -B-2 protein is constitutively phosphorylated and demonstrates tyrosine kinase activity without the presence of ligand when overexpressed in NIH3T3 cells (7 ) A possible role of c-erb -B-2 in human malignancy has been postulated, based on its identified amplification and overexpression in a variety of carcinomas (8 ). c-erb -B-2 overexpression may stimulate signal transduction pathways and lead to aberrant growth, resulting in the malignant phenotype. Human breast cancer has been shown to exhibit c-erb -B-2 overexpression in 20–30% of examined tumors (9 ,10 ). The prognostic significance of c-erb -B-2 overexpression in breast cancer has been investigated, and there appears to be a correlation between high levels of c-erb -B-2 expression and poor clinical outcome, particularly in patients with positive axillary lymph nodes (11 ,12 ).
        ad image
        提问
        扫一扫
        丁香实验小程序二维码
        实验小助手
        丁香实验公众号二维码
        扫码领资料
        反馈
        TOP
        打开小程序